PubMed Health⌕ Search

Biomedical subjects

S Kroll

Publications and source records attributed to S Kroll.

61 records · Page 4Linked to original sources

[Proteolytic activities of Ps. fluorescens in milk: determination with azocasein in comparison with HPA].

Proteolytic activity of psychotrophie bacteria in milk can be measured in a practical and comparatively sensitive manner using Azocasein as a substrate. The necessary parameters were exemplarily developed and demonstrated with a typical, strongly proteolytic strain of Pseudomonas fluorescens (No. 112). Comparison of the improved Azocasein method with a modified version of the HPA method of Cliffe and Law--they had proposed it for predicting the stability of UHT milk--showed nearly the same sensitivity with six test strains of Pseudomonas fluorescens. The first significant detection of proteolytic activity could be made approximately at the same time except with one strain of the biotype II (miscellaneous strains). It is discussed, whether the demonstrated methods can be judged (by the bacterial counts of detection) as sufficiently sensitive for to prediction of term spoilage during storage of UHT products.

Animals↗

Heat inactivation of exogenous proteinases from Pseudomonas fluorescens. I. Possibility of inactivation in milk.

The inactivation reaction of the proteinase of a P. fluorescens strain of biotype I in milk was investigated at 130-150 degrees C, also in milk and in buffer with and without added CaCl2 at temperatures below 100 degrees C. The decline in activity corresponded to first order kinetics in the UHT region; Ea = 115 kJ/mol. D values were 290 (130 degrees C), 124 (140 degrees C) and 54 s (150 degrees C); therefore, the usual temperature time combinations of UHT treatment are not sufficient to achieve the required rates of inactivation. At temperatures below 80 degrees C, inactivation corresponded increasingly to second order kinetics with considerably higher reaction rates; at 55 degrees C, an inactivation reaction corresponding to that induced by UHT treatment could be achieved at a thermal stress lower by a factor of 500. This "low temperature inactivation" was observed in a further 20 strains representing the spectrum of P. fluorescens. The average rates of inactivation following heat treatment in milk for 20 min are 47% at 55 degrees C and 44% at 60 degrees C. This can be regarded as the most effective temperature range for the inactivation of the proteinases in milk. Clear connections can be seen between the biotype groups and the optimum temperature for inactivation: biotype group I ca. 55 degrees C, group II (with a few exceptions) less than or equal to 50 degrees C and group III greater than or equal to 60 degrees C. The inactivation reaction is systematically influenced by the proteins and Ca++ ions present in milk.

Animals↗

Candidates for prostate radioactive seed implantation treated by external beam radiotherapy.

PURPOSE: We report the prostate-specific antigen-based freedom from biochemical failure after conventional and three-dimensional conformal external beam radiotherapy for patients who would have been candidates for 125I implantation monotherapy. MATERIALS AND METHODS: Patients included in the study were required to have prostate-specific antigen values < or = 20, T stage < or = 2b, and Gleason score sum of 2 to 6. All patients underwent external beam irradiation with curative intent and a minimum follow-up from completion of treatment of at least 1 year. In addition, all patients had to have pretreatment and follow-up prostate-specific antigen measurements and no history of hormonal manipulation, orchiectomy, or radical prostatectomy. A total of 187 patients meeting these criteria were treated between March 1988 and June 1995, and they form the study group for this analysis. Freedom from biochemical failure was defined as prostate-specific antigen value that failed to be maintained at 1 ng/mL or less or an increase in prostate-specific antigen value of 0.5 ng/mL or more in 1 year even if prostate-specific antigen value was less than 1 ng/mL. RESULTS: Among the 187 patients, the median pretreatment prostate-specific antigen value was 7.4 ng/mL (0.3-19.9 ng/mL). The median follow-up was 34 months. Twenty-three percent of patients had a Gleason score sum of 2 to 4, and 77% had a Gleason score sum of 5 to 6. Clinical stages were T1 in 33% and T2 in 67%. One hundred twenty-five patients were treated by conventional external beam radiotherapy with a median dose of 69.5 Gy (60-71 Gy), and 62 patients were treated by three-dimensional conformal external beam radiotherapy with a median dose of 76.4 Gy (71.6-87 Gy). The overall freedom from biochemical failure was 75% at 4 years. Rates of freedom from biochemical failure by pretreatment prostate-specific antigen levels were 91% for prostate-specific antigen value < or = 4 ng/mL, 65% for prostate-specific antigen value > 4 but < or = 10 ng/mL, and 30% for prostate-specific antigen value > 10 ng/mL. Pretreatment prostate-specific antigen value was a statistically significant prognosticator, with lower values associated with favorable freedom from biochemical failure outcome in univariate and multivariate analyses. Conventional versus three-dimensional treatment, T1 versus T2 stage, and Gleason score sum 2 to 4 versus 5 to 6 did not show statistically significant difference in freedom from biochemical failure. CONCLUSIONS: Although our overall results after external beam radiotherapy for early-stage prostate cancer patients are less favorable than the best results published for 125I implantation monotherapy, our results are comparable to those in most other studies with implantation monotherapy. This most likely results from selection bias as well as our stricter definition of freedom from biochemical failure. In addition, for our subset of patients, there was no statistically significant improvement in the 4-year freedom from biochemical failure with the use of higher doses.

Brachytherapy↗